PRESENTED AT ESMO 2016.
SLIDES ARE THE PROPERTY OF THE AUTHOR. PERMISSION REQUIRED FOR REUSE.
COMBI-v: Progression-Free Survival
(ITT population)
13
1.00
0.75
0.50
0.25
0.00
0
6
12
18
24
30
36
42
Months From Randomization
PFS Probability
Patients at risk, n
D + T
Vem
352
352
236
162
162
82
120
55
93
27
80
16
63
11
25
2
3-y PFS, 24%
3-y PFS, 10%
2-y PFS, 30%
2-y PFS, 16%
HR, 0.61 (95% CI, 0.51-0.73)
Dabrafenib + trametinib (n = 352)
Median PFS, 12.1 mo (95% CI, 9.7-14.7)
Vemurafenib (n = 352)
a
Median PFS, 7.3 mo (95% CI, 5.7-7.8)
a
Vemurafenib arm includes 34 patients (10%) who crossed over to the dabrafenib + trametinib arm.
